Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise.

Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates.

Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

Jeff He is the Co-founder and Chief Operating Officer of HiFiBiO Therapeutics. He brings more than 20 years of experience in finance, corporate strategy, and operations.

Previously, Mr. He co-founded Harbour BioMed and served as its Chief Financial Officer. Prior to that position, he was the Executive Vice President of ShangPharma/ChemPartner, a leading contract research organization (CRO) based in Shanghai. Mr. He also served as Senior Vice President at Texas Pacific Group (TPG), where he helped to privatize ShangPharma from the NYSE. Prior to TPG, Mr. He held management roles with increasing P&L responsibilities at Danaher/Fluke and Saint-Gobain. In his early career, he was a strategy consultant at Bain & Company and a senior financial analyst at Intel.

Mr. He received his MBA degree from Goizueta Business School at Emory University and his bachelor degree in engineering from Zhejiang University.

Dr. Luigi Manenti is the SVP, Global Head of Clinical Development at HiFiBiO Therapeutics. He is a seasoned physician scientist with extensive experience designing and executing innovative clinical trials with a strong expertise in translational clinical oncology.

Previously, Dr. Manenti served as the Team Leader for Solid Tumors in Global Pipeline Strategy at Novartis Oncology Business Unit where he oversaw the early commercial and pipeline strategy for various internal and external assets. Prior to this role, he worked at the Novartis Institutes for BioMedical Research as Global Clinical Program Leader, leading multiple programs including capmatinib (Tabrecta) and MBG453 (sabatolimab). His earlier roles include multiple positions at Roche in Switzerland and China including Translational Medicine Site head.

Dr. Manenti holds an MD in Medicine and Surgery from the University of Pavia.

Francisco Adrian is the Senior Vice President Global Head of Research at HiFiBiO Therapeutics. He is an accomplished scientist with more than 20 years of experience in drug discovery and pharmaceutical research and development.

Previously, Dr. Adrian worked as a Director at the Sanofi Oncology Division, where he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Before joining Sanofi, he was a Group Leader at the Genomics Institute of the Novartis Research Foundation focused on the discovery of novel kinase inhibitors for Oncology indications.

Dr. Adrian graduated in Organic Chemistry and Biochemistry and received his PhD in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris.

Dr. Christos Hatzis is the Vice President, Head of Clinical Pharmacogenomics at HiFiBiO Therapeutics. He is an engineer by training with extensive translational and immune-oncology experience and an entrepreneurial mindset.

Prior to HiFiBiO, Dr. Hatzis was a Director, Tumor Strategy Lead, Translational Medicine at Bristol-Myers Squibb where he provided scientific and strategic leadership for the solid tumor programs. Before BMS, he served as an Associate Professor for the Department of Internal Medicine (Medical Oncology) at Yale University School of Medicine, where he still holds an Adjunct faculty position. Earlier in his career, he co-launched two start-up companies, Silico Insights and Nuvera Biosciences, an informatics and data mining company and ventured-funded spin off the MDACC respectively.

John Pallante is the Vice President, Head of Clinical Operations at HiFiBiO Therapeutics. He has over 15 years of clinical operations experience preparing and executing global clinical trials alongside partners and collaborators.

Prior to HiFiBiO, Mr. Pallante served as the Global Head of Clinical Quality Management and Training at Novartis Institutes for BioMedical Research. Before then, he held various leadership roles at Novartis in the areas of Governance and Operational Excellence, Clinical Operations, and Clinical Trial Intelligence.

John Pallante earned his MS from Temple University and BS from Rutgers, The State University of New Jersey-Camden.

Xuqiong (Joanna) Wu is the General Counsel at HiFiBiO Therapeutics. She is an accomplished lawyer and scientist with more than 15 years of experience advising life sciences and biotechnology companies.

Previously, she held various in-house counsel positions at three organizations, including a global leader of machinery and engineering, a cutting-edge provider of patient-specific surgical instruments and orthopedic implants, and an emerging biotechnology company. Prior to those positions, Dr. Wu worked at the Boston office of Ropes & Gray LLP, where she advised a variety of clients in the life science industry on intellectual property and regulatory matters.

Dr. Wu received her Juris Doctor (JD) from the law school at the University of California at Berkeley with a certificate in Law & Technology. During law school, she was an editor for the Berkeley Technology Law Journal and the California Law Review, and worked as a law clerk for an intellectual property law firm in San Francisco. Before law school, she received her PhD in physiology from the University of Virginia and conducted research at the Lawrence Berkeley National Laboratory as a recipient of the Alexander Hollaender Distinguished Postdoctoral Fellowship awarded by the U.S. Department of Energy.

Andreas is leading the company’s global efforts to support pipeline progression by applying the latest advances in data science, machine learning and artificial intelligence on translationally relevant data sets. Dr. Raue brings more than 10 years of experience in computational science, as well as several years of industry leadership experience in immune-oncology antibody development at Merrimack Pharmaceuticals. Andreas received his PhD in theoretical physics from the University of Freiburg where he applied computational modeling and analysis to biological and medical problems. His research has been published in various scientific journals and presented at international conference. Dr. Raue is inspired by the potential of leveraging innovative single-cell technologies and machine learning for the advancement of cancer research.

Jinping Gan leads the global Antibody Discovery and Optimization organization at HiFiBIO. He is a biological chemist with 20 years of biopharma industry experience.

Jinping has strong expertise in drug metabolism, pharmacokinetics and pharmacodynamics, and chemical toxicology. Jinping previously worked at Bristol-Myers Squibb, focusing on preclinical optimization and characterization of diverse pipeline molecules from early discovery to NDA filings. Jinping held a PhD in Biological Chemistry from MIT , and a BS in Analytical Chemistry from University of Science & Technology of China.

Edward Rocnik is the Executive Director, Head of CMC at HiFiBiO Therapeutics. He is a seasoned scientist with over 12 years of experience in CMC and research related roles.

Previously, Dr. Rocnik has held various CMC and research roles at Takeda, Millennium, and Organogenesis. Most recently, he served as Director, Head of Late-Stage Analytical Development, Cell Therapies at Takeda.

Dr. Rocnik earned his PhD and BS from Western University.

Vincent Tse is the Director of Staff and Strategy at HiFiBiO Therapeutics. His professional experience includes R&D Product Development, Business Development, and Strategy Consulting for both small biotech and large pharma.

Vincent previously worked for Genentech, conducting competitive intelligence for the company’s asthma portfolio. Prior to Genentech, he performed Product and Business Development for Armata Pharmaceuticals, an innovative biotech focused on therapeutics against antibiotic-resistant infections. Most recently, he was a strategy and portfolio analysis consultant for IQVIA with diverse engagements in digital therapeutics, rare disease, and oncology.

Vincent earned an MBA from Duke University Fuqua School of Business, an MS in FDA Regulatory Affairs from Northeastern University, and a BS degree in Physiological Science from UCLA.